TB500

Name: TB500
Availability: InStock

2mg vial

TB-500 is a synthetic analogue representing the active region of Thymosin Beta-4 (Tβ4) - a 43-amino-acid regulatory protein expressed in virtually all human and animal cells. It has been studied for cell migration, angiogenesis, stem cell recruitment and the repair of muscle, tendon, ligament, cardiac and neural tissue.

Select size

Checking availability…

Researched for

Accelerated wound and dermal closure in Phase II research
Cardiomyocyte survival and repair in post-MI rodent models
Enhanced tendon, ligament and fascia recovery
Downregulation of TNF-α and IL-1β inflammatory mediators
Reduced infarct volume in stroke models; axonal growth support
Accelerated corneal epithelial healing in Phase II ocular trials

Mechanism of action

Sequesters G-actin monomers to regulate actin polymerisation dynamics, driving cell migration, angiogenesis and tissue remodelling. Upregulates MMP-2 and promotes progenitor cell recruitment at injury sites.

Research protocol

Common research protocols use a 2–2.5mg loading dose twice weekly for 4–6 weeks, followed by 1.5–2mg once weekly for maintenance. Cycles typically run 6–8 weeks with 4-week breaks. Route: subcutaneous or intramuscular.

Half-life

Plasma half-life approx. 30–80 minutes for free Tβ4, but SC/IM depot effects extend functional activity over several days per injection.

Reconstitution

Reconstitute a 5mg vial with 1–2mL bacteriostatic water for a 2.5–5mg/mL working concentration. Gently swirl; do not vortex.

Storage

Lyophilised: 2–8°C for routine storage, or -20°C for long-term (stable 18–24 months). Reconstituted: 2–8°C, use within 30 days.

Research considerations

• Transient post-injection 'head rush' or fatigue commonly reported, typically resolving within 30–60 minutes.
• Class-level caution flagged for subjects with active malignancy due to angiogenic mechanisms.
• Most outcome data derives from Tβ4 studies rather than the TB-500 fragment specifically - direct extrapolation requires caution.